Peregrine Pharmaceuticals Announces Closing of Preferred Stock Offering
February 19 2014 - 10:15AM
Marketwired
Peregrine Pharmaceuticals Announces Closing of Preferred Stock
Offering
TUSTIN, CA--(Marketwired - Feb 19, 2014) - Peregrine
Pharmaceuticals, Inc. (NASDAQ: PPHM) (the "Company"), announced
today that it has closed its previously announced underwritten
public offering of 700,000 shares of its 10.50% Series E
Convertible Preferred Stock (the "Series E Preferred Stock") at a
public offering price of $25.00 per share. The Company has filed an
application to list the shares of Series E Preferred Stock on the
NASDAQ Capital Market under the symbol "PPHMP". If approved by
NASDAQ, trading of the Series E Preferred Stock on the NASDAQ is
expected to begin within 30 days after the date of initial issuance
of the Series E Preferred Stock. Holders of Series E Preferred
Stock may convert their shares, in whole or in part, into shares of
the Company's common stock at a conversion price of $3.00 per
share, representing a conversion premium of 75 percent over the
last reported sale of Peregrine's common stock on February 10, 2014
(day prior to pricing). The aggregate gross proceeds from the
offering, before deducting underwriting discounts and commissions
and offering expenses payable by Peregrine, were approximately
$17.5 million.
MLV & Co. LLC acted as sole book-runner for the
offering.
Maxim Group LLC and National Securities Corporation, a wholly
owned subsidiary of National Holdings, Inc. (OTCBB: NHLD), acted as
lead managers for the offering and Empire Asset Management Company
and I-Bankers Securities, Inc. acted as co-managers for the
offering. Roth Capital Partners, LLC served as a financial advisor
to Peregrine.
The Company has also granted the underwriters a 30-day option to
purchase up to an aggregate of 105,000 additional shares of its
Series E Preferred Stock. The Company intends to use the net
proceeds from the offering for general corporate purposes.
The offering was made pursuant to the Company's existing
effective shelf registration statement, previously filed with the
Securities and Exchange Commission ("SEC"). A final prospectus
supplement related to the offering was filed with the SEC on
February 12, 2014 and is available on the SEC's website located at
www.sec.gov or from MLV &Co. LLC at 1251 Avenue of the
Americas, New York, NY 10020, Attn: Randy Billhardt.
About Peregrine Pharmaceuticals, Inc. Peregrine Pharmaceuticals,
Inc. is a biopharmaceutical company with a portfolio of innovative
monoclonal antibodies in clinical trials focused on the treatment
and diagnosis of cancer. The Company is pursuing multiple clinical
programs in cancer with its lead immunotherapy candidate
bavituximab while seeking a partner to further advance its novel
brain cancer agent Cotara®. Peregrine also has in-house cGMP
manufacturing capabilities through its wholly-owned subsidiary Avid
Bioservices, Inc. (www.avidbio.com), which provides development and
biomanufacturing services for both Peregrine and third-party
customers. Additional information about Peregrine can be found at
www.peregrineinc.com.
Safe Harbor Statement: Statements in this press release
which are not purely historical, including statements regarding
Peregrine Pharmaceuticals' intentions, hopes, beliefs,
expectations, representations, projections, plans or predictions of
the future are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. The
forward-looking statements involve risks and uncertainties
including, but not limited to, the risk that enrollment of the
Phase III trial may experience delays or take longer than
anticipated, the risk that the results from the Phase III trial may
not support a future Biologics License Application (BLA)
submission, the risk that the Company may not have or raise
adequate financial resources to complete the Phase III trial and
the risk that the Company may not find a suitable partner for the
Phase III trial or the PS program. It is important to note that the
Company's actual results could differ materially from those in any
such forward-looking statements. Factors that could cause actual
results to differ materially include, but are not limited to,
uncertainties associated with completing preclinical and clinical
trials for our technologies; the early stage of product
development; the significant costs to develop our products as all
of our products are currently in development, preclinical studies
or clinical trials; obtaining additional financing to support our
operations and the development of our products; obtaining
regulatory approval for our technologies; anticipated timing of
regulatory filings and the potential success in gaining regulatory
approval and complying with governmental regulations applicable to
our business. Our business could be affected by a number of other
factors, including the risk factors listed from time to time in our
reports filed with the SEC including, but not limited to, our
annual report on Form 10-K for the fiscal year ended April 30, 2013
and quarterly report on Form 10-Q for the quarter ended October 31,
2013. The Company cautions investors not to place undue reliance on
the forward-looking statements contained in this press release.
Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does
not undertake to update or revise any forward-looking statements in
this press release.
Contact: Christopher Keenan or Jay Carlson Peregrine
Pharmaceuticals (800) 987-8256 info@peregrineinc.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to Apr 2024